TICKERNERD
Menu
JANXJANXHealthcare · Biotechnology

JANX Stock Forecast: Janux Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$17
−3.28% on the day

The 18 Wall Street analysts covering Janux Therapeutics, Inc. hold a median 12-month price target of $29 — +69.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 70 of 100 as at 12 Sept 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$1.0B
Ticker Nerd rank
70 / 100
Median analyst target
$29
Analysts covering
18
Revenue$10.3M
Operating income−$31.7M
Net income−$22.0M
Free cash flow$12.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−13.6%
1M
+3.5%
YTD
+23.9%
1Y
−31.9%
From 52W high
−50.8%
From 52W low
+40.4%
$12
$35
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

JANX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Janux Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
70 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
93
Quality
90
Accruals
77
Value
71
Revisions
48
Issuance
45
Size
44
Volatility
33
Momentum
26

Growth (93): Sales and profits are climbing, and climbing faster than before.

Momentum (26): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

JANX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on JANX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Oct 25Jan 26Apr 26Jul 26JANXHigh $75Median $29Low $14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says18 analysts
16 Buy1 Hold1 Sell
Low $14Median $29High $75

The green dot is the last close — the median target sits +69.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 Aug 2026Wolfe ResearchUpgradeOutperform$23
7 Aug 2026GuggenheimMaintainsBuy$58 → $55
7 Aug 2026GuggenheimMaintainsBuy—
25 June 2026Truist SecuritiesAssumesBuy$80 → $26
8 May 2026GuggenheimMaintainsBuy—
8 May 2026Piper SandlerMaintainsOverweight—
8 May 2026WedbushMaintainsOutperform—
28 Apr 2026Jones TradingMaintainsBuy—
20 Apr 2026BarclaysDowngradeUnderweight—
15 Apr 2026UBSDowngradeNeutral—
27 Feb 2026Cantor FitzgeraldMaintainsOverweight—
27 Feb 2026GuggenheimMaintainsBuy—
20 Jan 2026Clear StreetDowngradeHold—
16 Jan 2026Piper SandlerMaintainsOverweight—
17 Dec 2025BarclaysMaintainsOverweight—
2 Dec 2025B of A SecuritiesMaintainsBuy—
2 Dec 2025Cantor FitzgeraldMaintainsOverweight—
2 Dec 2025Clear StreetMaintainsBuy—
2 Dec 2025HC Wainwright & Co.MaintainsBuy—
2 Dec 2025StifelMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. JANX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

JANX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Janux Therapeutics, Inc. returned −31.9% against +17.5% for the S&P 500, dividends included.

JANX vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140Oct 25Jan 26Apr 26Jul 26JANXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

JANX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
7
Analysts cutting
5
Fundamentals

Janux Therapeutics, Inc. (JANX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−9.3×

Cheaper than 92% of US stocks

Price / sales
43.6×

Cheaper than 6% of US stocks

Price / book
1.1×

Cheaper than 69% of US stocks

EV / EBITDA
−0.7×

Cheaper than 65% of US stocks

Growth & margins
Revenue growth (YoY)
175.0%

Higher than 95% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−308.7%

Higher than 9% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−10.7%

Higher than 35% of US stocks

Return on assets
−8.8%

Higher than 28% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Janux Therapeutics, Inc. (JANX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Janux Therapeutics, Inc. has a market value of $1.0B and an enterprise value of $95.5M.

  • Revenue in the twelve months to 30 June 2026: $24.0M. The latest quarter grew 175.0% year on year.

  • Net income over the same four quarters: −$102.6M, a −427.5% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.64.

  • Free cash flow in the twelve months to 30 June 2026: −$41.9M.

  • Janux Therapeutics, Inc. spent $0.0 on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 61.1M.

  • Trailing P/E: −9.3×; forward P/E: −6.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Janux Therapeutics, Inc. employs 113 people — $212K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

JANX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
JANXJanux Therapeutics, Inc.$1.0B
70
MLTXMoonLake Immunotherapeutics$1.0B
15
ATTOAttovia Therapeutics, Inc.$1.0B
0
SVRASavara, Inc.$1.0B
35
KURAKura Oncology, Inc.$1.0B
79
ABUSArbutus Biopharma Corp.$1.0B
92
CRVSCorvus Pharmaceuticals, Inc.$1.1B
54

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Janux Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest JANX news & analysis

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013

Business Wire · 14 Sept 2026positive

Janux Therapeutics announced that the first patient has been dosed in the Phase 1 clinical trial of JANX013, its PSMA-targeted tumor-activated CD28 co-stimulatory bispecific, in patients with metastatic castration-resistant prostate cancer. The program is initially being developed in combination with JANX007.

Why it matters — This marks a clinical milestone for Janux's JANX013 program and its combination approach with JANX007 in metastatic castration-resistant prostate cancer.

JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know

Zacks Investment Research · 21 Aug 2026positive

Janux Therapeutics shares rose 19.1% over the past three months, according to a Zacks Investment Research report. The gain is attributed to pipeline progress, upcoming catalysts, and a strong cash position that have boosted investor confidence.

Why it matters — A JANX watcher would care because the share-price gain reflects growing investor confidence in the company's pipeline progress, upcoming catalysts, and financial stability.

Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research · 6 Aug 2026negative

Janux Therapeutics reported a Q2 loss of $0.35 per share, wider than the Zacks Consensus Estimate of a $0.26 loss, though an improvement from the $0.55 per share loss in the year-ago quarter.

Why it matters — The quarterly results missed analyst estimates, giving JANX watchers an updated view of the company's recent financial performance.

Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Business Wire · 6 Aug 2026neutral

Janux Therapeutics reported its financial results for the quarter ended June 30, 2026, and provided a business update. CEO David Campbell said the company continued to execute across its clinical portfolio while preparing for multiple upcoming milestones, with patient enrollment progressing.

Why it matters — JANX watchers would care because the update signals ongoing clinical trial enrollment and highlights upcoming pipeline milestones for the immunotherapy developer.

FAQ

Frequently asked questions about JANX stock

What is the JANX stock price forecast for 2026-2027?

The 18 Wall Street analysts covering Janux Therapeutics, Inc. have a median 12-month price target of $29, with estimates ranging from $14 to $75. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is JANX stock a buy right now?

Of the 18 analysts covering Janux Therapeutics, Inc., 16 rate it a Buy, 1 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Janux Therapeutics, Inc. 70 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank JANX?

As at 12 Sept 2026, Janux Therapeutics, Inc. ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (93 of 100).

Will JANX stock go up?

No one can know that. What the data says: the median 12-month target from 18 analysts implies +69.6% from the last close, and Ticker Nerd's factor model ranks Janux Therapeutics, Inc. 70 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the JANX stock forecast for 2030?

No analyst covering Janux Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JANX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $75 over the next 12 months.

How has JANX stock performed over the past year?

Janux Therapeutics, Inc. returned -31.9% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Janux Therapeutics, Inc. do?

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision-engineered immunotherapies for cancer.

What is the latest news on JANX?

The most recent item we track (Business Wire, 14 Sept 2026): "Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013". Janux Therapeutics announced that the first patient has been dosed in the Phase 1 clinical trial of JANX013, its PSMA-targeted tumor-activated CD28 co-stimulatory bispecific, in patients with metastatic castration-resistant prostate cancer. The program is initially being developed in combination with JANX007.

Company

About Janux Therapeutics, Inc.

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision-engineered immunotherapies for cancer. The company’s core programs are built around its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, which are designed to activate immune responses selectively in tumors while limiting effects on healthy tissue. Janux Therapeutics is advancing a pipeline of investigational candidates that target a range of cancers, including solid tumors and prostate cancer, and its research also extends to autoimmune disease applications. The company works through preclinical and early clinical development activities, supported by collaboration and discovery efforts, positioning it as a platform-driven biotechnology business centered on novel immune-oncology research.

CEO Dr. David Alan Campbell Ph.D. · 113 employees · United States · https://www.januxrx.com